Search

Background and Objectives: Comorbidity of substance use disorders and depression is a common phenomenon. It is well known that opioid addiction is neurobiologically distinct from psychostimulant addiction. However, direct comparisons of comorbid depressive symptoms in patients with methamphetamine (METH) use disorder (MAUD) and heroin use disorders (HUD) have been lacking until now. Methods: A total of 353 patients with methamphetamine use disorder, 76 patients with HUD, and 203 healthy controls were recruited. The Beck Depression Inventory (BDI‐SF), the Desires for Drug Questionnaire (DDQ) and the short form of the Childhood Trauma Questionnaire (CTQ‐SF) were used to measure participants' depressive symptoms, drug craving, and childhood abuse or neglect, respectively. Results: The prevalence of depressive symptoms was 35.41% (125/353) in MAUD and 56.57% (43/76) in MAUD, significantly higher than the 22.66% (46/203) in healthy controls. Furthermore, there was a significant difference in the total BDI score between the MAUD and HUD groups (F = 5.02, df = 1, 372, p =.026). Among MAUD, years of education, history of incarceration, month of abstinence and negative reinforcement scores were associated with depressive symptoms (all p <.05). Among HUD, duration of drug use, childhood emotional abuse and sexual abuse were associated with depressive symptoms (all p <.05). Conclusions and Scientific Significance: The prevalence and correlates of depressive symptoms differ between MAUD and HUD, adding to the existing literature. Therefore, treatment and intervention programs should be designed to address these unique correlates in HUD and MAUD patients. [ABSTRACT FROM AUTHOR]

Background and Objectives: Methamphetamine (MA) is one of the most common addictive substances and has become the second most commonly used drug worldwide. Obsessive‐compulsive disorder (OCD) has been shown to influence the effectiveness of addiction treatment, and there may be overlapping neurobiological mechanisms between OCD and addiction. The aim of this study was to investigate the prevalence and clinical correlates of OCD among MA patients. Methods: A total of 457 MA patients were recruited, and clinical and demographic data were collected. The Yale‐Brown Obsessive‐Compulsive Scale was utilized for OCD symptoms, and the Obsessive‐Compulsive Drug Use Scale was used for MA craving. Results: The prevalence of OCD among MA patients was 7.7%. Compared to those patients without OCD, patients with OCD had a longer length of abstinence and higher OCDUS frequency of craving subscale and total scores. Multiple regression showed that longer length of abstinence and higher MA carving were independently associated with OCD in MA patients. Discussion and Conclusions: Chinese Han MA patients have a high prevalence of OCD. Some clinical parameters may be associated with OCD in MA patients. Scientific Significance: This is the first study to examine the prevalence, sociodemographic and clinical correlates of OCD in MA patients in a Chinese Han population. [ABSTRACT FROM AUTHOR]

Background and Objectives: The aim of this study was to investigate the prevalence of posttraumatic stress disorder (PTSD) and clinical correlates in Chinese methamphetamine patients. Methods: We analyzed 481 Chinese methamphetamine patients. Results: The prevalence of PTSD among Chinese methamphetamine patients was 7.90% (38/481), which was higher than in western countries. Binary logistic regression showed that age, smoking, abstinence time, age of onset, and DDQ control dimensions were associated with PTSD. Conclusions and Scientific Significance: Our results indicated that some demographic and clinical variables were associated with PTSD in Chinese methamphetamine patients, which provided evidence for PTSD comorbidity with methamphetamine. [ABSTRACT FROM AUTHOR]

Background and Objectives: Antisocial personality disorder (ASPD) is very common among methamphetamine (MA) patients, but very few studies have been conducted in China. This study aimed to investigate the prevalence and clinical correlates of ASPD among Chinese MA patients. Methods: We recruited 627 MA patients and collected demographic and MA use data through one‐on‐one semi‐structured interviews. ASPD was measured by the Mini International Neuropsychiatric Interview (M.I.N.I.). The Desires for Drug Questionnaire (DDQ) and visual analog scale (VAS) were used to assess drug cravings. Results: The prevalence rate of ASPD among MA patients was 27.59% (173/627). Patients with ASPD had greater age at the first onset, duration of MA use, length of abstinence, VAS, DDQ desire and intention, negative reinforcement, and total DDQ scores than patients without ASPD. Stepwise binary logistic regression analysis revealed that age, age at the first onset, length of abstinence, and DDQ‐negative reinforcement were independently associated with ASPD in MA patients. Discussion and Conclusions: Our findings suggest that the prevalence of ASPD is high among Chinese MA patients. Furthermore, some demographic and clinical variables are associated with ASPD in MA patients. Scientific Significance: We focused our study on the clinical profile of ASPD and the reasons for its high prevalence in Chinese methamphetamine patients. We identified several demographic and clinical variables as correlates of the occurrence of ASPD in methamphetamine patients, which provides evidence for ASPD comorbidity in methamphetamine patients. [ABSTRACT FROM AUTHOR]